Selectivity of opioid agonists and antagonists for the various opioid receptor types
Takemori, A.E.; Portoghese, P.S.
Psychopharmacology Bulletin 21(3): 464-465
1985
ISSN/ISBN: 0048-5764
PMID: 2994158
Accession: 041325034
PDF emailed within 1 workday: $29.90
Related References
van Niel, J.C.G.; Schneider, J.; Tzschentke, T.M. 2016: Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence Drug Research 66(11): 562-570Holzgrabe, U.; Nachtsheim, C.; Siener, T.; Drosihn, S.; Brandt, W. 1997: Opioid-agonisten und -antagonisten, opioid-rezeptoren - Opioid agonists, antagonists and opioid receptors Pharmazie 52(1): 3-22
Kumar, V.; Clark, M.J.; Traynor, J.R.; Lewis, J.W.; Husbands, S.M. 2014: Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists Bioorganic and Medicinal Chemistry 22(15): 4067-4072
Harland, A.A.; Yeomans, L.; Griggs, N.W.; Anand, J.P.; Pogozheva, I.D.; Jutkiewicz, E.M.; Traynor, J.R.; Mosberg, H.I. 2015: Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities Journal of Medicinal Chemistry 58(22): 8952-8969
Le Bourdonnec, B.; Barker, W.M.; Belanger, S.; Wiant, D.D.; Conway-James, N.C.; Cassel, J.A.; O'Neill, T.J.; Little, P.J.; DeHaven, R.N.; DeHaven-Hudkins, D.L.; Dolle, R.E. 2008: Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles Bioorganic and Medicinal Chemistry Letters 18(6): 2006-2012
Ben-Sreti, M.M.; Sewell, R.D. 1982: Stereospecific inhibition of oxotremorine-induced antinociception by (+)-isomers of opioid antagonists: comparison with opioid receptor agonists Journal of Pharmacy and Pharmacology 34(8): 501-505
Li, T.; Jinsmaa, Y.; Nedachi, M.; Miyazaki, A.; Tsuda, Y.; Ambo, A.; Sasaki, Y.; Bryant, S.D.; Marczak, E.; Li, Q.; Swartzwelder, H.S.; Lazarus, L.H.; Okada, Y. 2007: Transformation of mu-opioid receptor agonists into biologically potent mu-opioid receptor antagonists Bioorganic and Medicinal Chemistry 15(3): 1237-1251
Portoghese, P.S.; Moe, S.T.; Takemori, A.E. 1993: A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists Journal of Medicinal Chemistry 36(17): 2572-2574
Shippenberg, T.S. 1987: Opioid agonists and mixed agonist antagonists identification of the receptor types mediating their reinforcing and aversive effects Naunyn-Schmiedeberg's Archives of Pharmacology 335(Suppl): R92
Ito, S.; Mori, T.; Sawaguchi, T. 2006: Differential effects of micro-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice Behavioural Pharmacology 17(8): 691-701
Olmsted, S.L.; Takemori, A.E.; Portoghese, P.S. 1993: A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists Journal of Medicinal Chemistry 36(1): 179-180
Varga, E.V.; Li, X.; Stropova, D.; Zalewska, T.; Landsman, R.S.; Knapp, R.J.; Malatynska, E.; Kawai, K.; Mizusura, A.; Nagase, H.; Calderon, S.N.; Rice, K.; Hruby, V.J.; Roeske, W.R.; Yamamura, H.I. 1996: The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists Molecular Pharmacology 50(6): 1619-1624
Khotib, J.; Narita, M.; Suzuki, M.; Yajima, Y.; Suzuki, T. 2004: Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors Neuropharmacology 46(4): 531-540
Yuan, Y.; Zaidi, S.A.; Elbegdorj, O.; Aschenbach, L.C.K.; Li, G.; Stevens, D.L.; Scoggins, K.L.; Dewey, W.L.; Selley, D.E.; Zhang, Y. 2013: Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity Journal of Medicinal Chemistry 56(22): 9156-9169
Maguire, D.R.; France, C.P. 2014: Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists Journal of Pharmacology and Experimental Therapeutics 351(2): 383-389
Shi, S.; Xu, J.; Feng, L.; Fan, X.; Chen, Z.; Qin, Y.; Chung, N.N.; Li, T.; Schiller, P.W. 2020: Novel µ opioid antagonists derived from the µ opioid agonists endomorphin and [Dmt1 ]DALDA (H-Dmt-D-Arg-Phe-Lys-NH2 ) Chemical Biology and Drug Design 96(5): 1305-1314
Tseng, C.S.; Tso, H.S. 1993: Effects of opioid agonists and opioid antagonists in endotoxic shock in rats Ma Zui Xue Za Zhi 31(1): 1-8
Ruan, X.; Luo, J.; Kaye, A.D. 2017: Efficacy and Tolerability of Co-Administering Full µ-Opioid Receptor Agonists with Buprenorphine and Mixed Opioid Agonists Drug Research 67(3): 189-190
Gowing, L.; Ali, R.; White, J. 2000: Opioid antagonists and adrenergic agonists for the management of opioid withdrawal Cochrane Database of Systematic Reviews 2: Cd002021
Wood, P.L. 1983: Opioid receptor affinities of kappa agonists, agonist/antagonists and antagonists in vitro and in vivo Progress in Neuro-Psychopharmacology and Biological Psychiatry 7(4-6): 657-662